SCHEMBL203719

SCHEMBL203719

O=Cc1ncc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.47
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
XDH P47989 1/20 0.35
ALDH5A1 P51649 1/20 0.35
ABAT P80404 1/20 0.35
VCAM1 P19320 1/20 0.35
AKR1B1 P15121 1/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP3A4 P08684 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALOX15 P16050 1/20 0.34
PRKDC P78527 1/20 0.34
HSD17B10 Q99714 1/20 0.34
S100A4 P26447 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27859421 0.84 ERN1 (0.39) ERN1KMT2AMEN1POLBPKM
SCHEMBL204607 0.84 ERN1 (0.39) ERN1KMT2AMEN1POLBPKM
SCHEMBL26088156 0.80 PRSS1 (0.37) ERN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL18235078 0.79 ERN1 (0.36) ERN1KMT2AMEN1POLBPKM
SCHEMBL29956553 0.79 SMN1; SMN2 (0.51) XDHALDH5A1ABATVCAM1ALDH1A1
SCHEMBL203806 0.79 VCAM1 (0.42) ERN1POLBXDHALDH5A1ABAT
SCHEMBL1991890 0.79 TDP1 (0.39) ERN1KMT2AMEN1POLBPKM
SCHEMBL2569899 0.78 MAPT (0.38) ERN1KMT2AMEN1POLBPKM
SCHEMBL14764234 0.78 MAPT (0.38) ERN1KMT2AMEN1POLBPKM
SCHEMBL30018808 0.78 MAPT (0.38) ERN1KMT2AMEN1POLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235719-A1 DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2025-11-13 WO disclosed
CN-120058698-A Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2025-05-30 CN disclosed
CN-118019532-B Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2025-03-18 CN disclosed
CN-119371420-A Naphthyridones derivative and preparation method thereof 上海翰森生物医药科技有限公司 2025-01-28 CN disclosed
EP-4408420-A1 AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-08-07 EP disclosed
US-20240228486-A1 SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS ENLIVEN INC (US) 2024-07-11 US disclosed
US-20240228486-A1 SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS ENLIVEN INC (US) 2024-07-11 US disclosed
CN-118019532-A Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2024-05-10 CN disclosed
EP-4326720-A1 PARP1 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-02-28 EP disclosed
CN-117177972-A PARP1 inhibitors and uses thereof 新特拉有限公司 2023-12-05 CN disclosed
US-8283475-B2 Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof MERIAL LIMITED (US) 2012-10-09 US disclosed
US-20120149750-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2012-06-14 US disclosed
US-8088801-B2 Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof MERIAL LIMITED (US) 2012-01-03 US disclosed
CN-102272105-A enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds 2011-12-07 CN disclosed
EP-2364301-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS Merial Limited (US) 2011-09-14 EP disclosed
WO-2010056999-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS MERIAL LIMITED (US) 2010-05-20 WO disclosed
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2010-05-20 US disclosed
EP-2155699-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF Merial Limited (US) 2010-02-24 EP disclosed
US-20080312272-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2008-12-18 US disclosed
WO-2008144275-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL LIMITED (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228486-A1 SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS PARP2, PARP1, PARP12 ERN1 1947/4885KMT2A 367/4885MEN1 2095/4885
US-20120149750-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4X1, CBR3, TYR ERN1 4088/4885KMT2A 278/4885MEN1 3363/4885
US-20080312272-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4X1, CBR3, TYR ERN1 4088/4885KMT2A 278/4885MEN1 3363/4885
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4B1, NPY4R, CYP4X1 ERN1 4324/4885KMT2A 261/4885MEN1 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.